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 Surgical intervention is the treatment of choice for patients with melanomas. However, the prognoses of the patients 
with melanomas at the IIC–IV stage, even after a complete resection of the lesions, is very diverse and, to a great degree, 
connected with a high risk of disease recurrence. The positive results of the studies in this area have resulted  in systemic 
adjuvant therapy becoming the standard for patients in this group. New methods of systemic treatment – both the mo-
lecularly targeted treatment with BRAF and MEK inhibitors (dabrafenib with trametinib) and anti-PD-1 immunotherapy 
(nivolumab or pembrolizumab) – are already registered in the United States and the European Union. Also the results of 
the studies concerning the use of preoperative systemic treatment in patients with loco-regionally advanced melanomas 
seem to be very promising.
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Introduction
Surgical intervention is the treatment of choice in patients with 
melanomas. However, the prognoses of patients with mela-
nomas at the IIC–IV stage, even after a complete resection of 
the lesions, is very diverse and, to a great degree, connected 
with a high risk of disease recurrence [1–5]. Currently, systemic 
adjuvant treatment after surgical intervention in the group of 
patients with a high risk of disease recurrence, has become the 
treatment standard. A novel approach to the treatment of mela-
nomas with locoregional advancement are studies concerning 
the implementation of a systemic preoperative treatment. Given 
the combination of the surgical intervention and conservative 
treatment, the core binding standard should be the manage-
ment of the disease by multi-specialist teams whose members 
are experienced in the diagnostics and treatment of patients 
with melanomas with locoregional and systemic spread.
Neoadjuvant treatment 
Neoadjuvant treatment has been growing in significance in 
cases of borderline resectable tumours or locally advanced 
locoregional stage III metastases. The results of the II phase trials 
published in 2018–2019 point out that the use of combined 
preoperative treatment with BRAF and MEK inhibitors (with the 
presence of the BRAF mutation) or anti-PD-1 immunotherapy in 
combination with z anti-CTLA-4 treatment, leads to a response 
to therapy in a significant  of patients whilst complete patholo-
gical remissions are connected with better prognoses. 
The report of Amaria et al. [6] presents the results of neo-
adjuvant treatment with dabrafenib and trametinib applied in 
patients with resectable III and IV stage melanomas (with the 
exception of the metastases in the brain and bones) with the 
presence of the BRAF mutation. This treatment was carried out 
within II phase clinical trials with a random patient selection.
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Seven patients were randomly selected for a standard 
surgical intervention with possible adjuvant treatment whilst 
14 patients  – for preoperative treatment with dabrafenib with 
trametinib, and then (after the resection) for  an adjuvant treat-
ment for up to one year. The trial was prematurely terminated 
on account of a significantly longer event-free survival (EFS) in 
the neo-/adjuvant arm in comparison with the standard treat-
ment arm. After a follow-up period with the median follow-up 
of 18.6 months, the rate of patients who survived in the arm 
which underwent neo-/adjuvant treatment (71%; 10/14) was 
significantly larger than the rate of patients surviving in the 
group treated according to standard methods (0). The median 
EFS was 19.7 months vs. 29 months respectively (p < 0.001). 
The neo-/adjuvant treatment with dabrafenib with trametinib 
was well tolerated. A radical surgical intervention in this group 
was performed in 12 patients and in 7 cases (58%) a complete 
pathological response was observed, which also gave better 
prognoses. 
Similar results were obtained in the II phase trial, NeoCombi 
[7], in which patients in the IIB–C stage with confirmed BRAF 
mutation, received dabrafenib with trametinib for 12 weeks 
before the resection of metastases and 40 weeks after the 
surgery. The study comprised 35 patients and in 30 of them 
(86%), the response to the preoperative treatment, according 
to the RECIST criteria, was observed, whilst in 17patients (49%) 
a pathological complete response (pCR) was found. The rate 
of the 2-year progression-free survival was 43.4%, with better 
results observed in the group of patients with the complete 
pathological response. 
Two other studies evaluated the use of preoperative im-
munotherapy. The first of them [8] concerned the application 
of preoperative nivolumab (up to 4 doses) in comparison with 
ipilimumab together with nivolumab (up to 3 doses) in 23 pa-
tients with resectable stage III or IV melanomas. The treatment 
with ipilimumab with nivolumab was connected with a high 
response rate (73%; pCR 45%), yet with significant toxicity (73% 
adverse events [AE] with grade 3.), whilst monotherapy with 
nivolumab gave much fewer responses (25%, pCR 25%), yet its 
toxicity was low (8% AE in stage 3.). The latter study, [9] OpACIN-
-neo, evaluated the best regime with the use of nivolumab in 
connection with ipilimumab with the use of randomisation: 
• in group A: 2 ipilimumab cycles 3 mg/kg body weight, plus 
nivolumab 1 mg/kg body weight every 3 weeks;
• in group B: 2 ipilimumab cycles 1 mg/kg body weight, plus 
nivolumab 3 mg/kg body weight, every 3 weeks;
• in group C: 2 ipilimumab cycles 3 mg/kg body weight, 
every 3 weeks and then 2 ipilimumab cycles 3 mg/kg body 
weight, every 2 weeks. 
The study comprised 86 patients in stage III of the disease 
with clinically confirmed metastases in regional lymph nodes. 
Within the first 12 weeks, immune-related adverse events (irAE), 
grade 3–4 were found in 40% of patients in group A, 20% in 
group B, and 50% in group C. Objective radiological response 
to treatment was obtained in 63% of patients in group A, 57% 
in group B, and 35% in group C. A pathological response was 
found in a larger rate of patients than a radiological response. 
In 57% of patients in group B, pCR was confirmed. None of 
these groups obtained the median event-free survival (EFS) 
or median relapse free survival (RFS).
During the follow-up period, symptoms of a relapse were 
observed in none of the patients. The B regimen seems to be 
the most preferred option for further studies. 
Moreover, in some patients neoadjuvant treatment seems to 
be more efficient than adjuvant therapy (which might be con-
nected with the activity of the immune system). What is more, 
this is a short lasting therapy and, as such is cost-effective. This 
type of treatment allows also for a better prognostic/predictive 
evaluation and personalisation of the follow-up examinations 
after therapy; in particular no complete histopathological re-
sponse was obtained and a patient might require adjuvant 
treatment (e.g. radiotherapy or targeted treatment with BRAF 
and MEK inhibitors after preoperative immunotherapy). In the 
entire studied patient population group, within the neoadjuvant 
treatment (table I), the rate of complete pathological remissions 
was 41% (38% after immunotherapy and 47% after molecularly 
targeted treatment). This strategy, however, requires further 
research with the participation of randomly selected patients 
and a comparison with postoperative adjuvant treatment.
Table I. The most important clinical trial concerning neoadjuvant treatment of melanoma with locoregional spread 
Clinical trial Treatment regime n pCR 
(%)
Median RFS 
(months)
Median follow-up 
(months)
Amaria Lancet Oncol 2018 [6] Dabrafenib/trametinib 21 58 19.7 18.6
Long Lancet Oncol 2019 [7] Dabrafenib/trametinib 35 49 23.0 27.0
Blank Nat Med 2018 [10] Ipilimumab + nivolumab 10 33 NR 32
Amaria Nat Med 2018 [8] Nivolumab/ipilimumab + nivolumab 12
11
25
45
NR
NR
20
Huang Nat Med 2019 [11] Pembrolizumab 30 19 NR 18
Rozeman Lancet Oncol 2019 [9] Ipilimumab + nivolumab 86 57 NR 8.3
pCR – complete remission in histopathological assessment, RFS – recurrence free survival, NR – not reached
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Adjuvant radiotherapy 
In individualised cases, after surgical treatment of patients with 
high-risk melanomas, it is possible to use adjuvant radiotherapy 
(RTH) – the dosage pattern comprises a hypofractionation at 
3–8 Gy/fraction or conventional fractionation depending on 
the location of the lesions. Indications for adjuvant RTH after 
resection of the primary tumour may comprise: 
• a diagnosis of the desmoplastic melanoma resected with 
narrow margins, 
• the presence of “positive” surgical margins (especially after 
the resection of local relapse) with the lack of any possibi-
lity of radicalisation of surgical intervention,  
• the presence of satellite foci, 
• sever neurotropism, or:
• location in the area of head and neck (note: RTH is the ole 
method of treatment and may be applied in the cases 
extensive lentigo malignant melanoma (LMM). 
In the case of the resection of local lesions and lymphade-
nectomy in the case of metastases in regional lymph nodes, 
the indications for adjuvant RTH may comprise: 
• the presence of extracapsular infiltration of the tumour, 
• the involvement of ≥4 lymph nodes (IIIC stage), 
• metastases diameter >3 cm, 
• metastases were found in the lymph nodes of the neck 
(from 2 lymph nodes involved with metastases or in the 
case of  metastases size of at least 2 cm), 
• a relapse after a previous resection [1, 2, 4, 12]. 
The results of one completed study with a random se-
lection of patients in which the value of the adjuvant radio-
therapy was evaluated (48 Gy in 20 fractions) after a lympha-
denectomy in the case of a high risk of melanoma relapse, 
confirmed the improvement of the local control after the 
radiation therapy. At the same time, no effect from radiothera-
py on the overall survival was observed. That said, an increase 
in the frequency of distant locoregional complications and 
a deterioration of the patient’s quality of life were observed. 
These results suggest that the use of adjuvant radiotherapy 
should be limited [13, 14]. It must also be stressed that there 
are no indications for RTH undertaken after the completion 
of a lymphadenectomy (CLND) resulting from the positive 
result of a sentinel node biopsy.
Systemic adjuvant therapy
Currently, systemic adjuvant therapy is a standard treatment in 
clinical practice for patients after a radical resection of primary 
lesions and a lymphadenectomy, whilst adjuvant radiothera-
py might be considered solely in the strictly defined cases 
described above. The results of recently published clinical 
trials point to an improvement in therapy results through 
the use of immunotherapy with immune system checkpoint 
inhibitors as well as combined treatment with BRAF and MEK 
inhibitors [1–4].
Interferon
For many years, apart from interferon (IFN), no other agents 
had been effective in the treatment of high risk skin mela-
nomas. Interferon (mainly alfa-2b IFN only in monotherapy) 
used for adjuvant treatment of patients with melanomas 
(for a  highly selected group) leads to (in a repetitive way) 
prolongation of the  relapse-free survival (RFS) in the majo-
rity of patients (table I) [4, 15–19]. However, evidence for the 
improvement of overall survival (OS) as a result of the use 
of IFN is much weaker and more controversial. In 10 out of 
17 evaluated studies, an improvement in RFS was observed, 
and the recent results of meta-analysis point to a decrease 
of the risk of relapse by 17–18% (relative risk [hazard ratio, 
HR]: 0.82–0.83; p < 0.0001) after the use of IFN in adjuvant 
treatment. Evidence for an improvement in OS comes mostly 
from meta-analyses and translates into an OS improvement 
of about 3% within 5 years within  the entire patient group. 
The use of IFN in adjuvant treatment in all patients with high 
risk melanomas is therefore not justified (especially given 
a significant toxicity of the treatment) and thus becomes only 
some option in selected patients. 
On the basis of the positive results of one of the three 
studies carried out by the Eastern Cooperative Oncology 
Group (ECOG): ECOG 1684, Interferon alfa-2b (IFN α-2b) ad-
ministered in high doses was registered in the United States 
and the European Union for the treatment of melanomas 
in IIB–III stage, whilst in small doses it was registered in the 
European Union for patients in stage II of the disease. The 
basis for the registration was the prolongation of the overall 
survival in a 7-year follow-up period, which, however, was not 
confirmed after a longer period of time (12 years). The results 
of the metanalyses show that the basic group for which the 
adjuvant treatment with IFN is beneficial are patients with an 
ulcerated primary focus of melanoma, in particular those with 
metastases which are not clinically overt (former terminology: 
micro-metastases) and not with clinically overt metastases 
observed in the enlarged lymph nodes (former terminology: 
macro-metastases) [17, 18]. 
Currently, the results of the 18081 study of the European 
Organisation for Research and Treatment of Cancer are expec-
ted, concerning the evaluation of the use of the pegylated IFN 
form in the treatment of patients after resection of a primary 
skin melanoma with ulceration without metastases in the re-
gional lymph nodes (the study recruitment was discontinued). 
The most frequent adverse effects of IFN comprise of 
flu-like symptoms, fever, fatigue, neutropenia, hepatoxicity 
and depression. Some part of the IFN toxicity profile changes 
within the course of treatment. Together with the length of the 
treatment, the flu-like symptoms recede whilst others reported 
adverse events remaining unchanged or even increasing with 
the length of treatment (mainly: fatigue, anorexia, symptoms 
of depression/anxiety).
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Immunotherapy with immune system 
checkpoint inhibitors 
In 2015 the results of the study became available concerning 
the use of adjuvant therapy with anti-CTLA-4 antibody (ipili-
mumab) after a lymphadenectomy due to metastases in the 
regional lymph nodes  (III stage). 951 patients were enrolled in 
the study, and they were randomised to the group with a high 
dose of ipilimumab: 10 mg/kg of body mass for 3 weeks and 
then every 3 months up to 3 years (n = 476) or to the placebo 
group (n = 476). With the median follow-up period of 2.7 years, 
234 events in relation to the RFS in the group with ipilimumab 
were observed in comparison with 294 events in the group 
with placebo; the median RFS was 26.1 months versus 17.1 
months, respectively (p = 0.0013). The improvement of RFS 
concerned both the patients with macro-, and micro-metasta-
ses (definitions according to the TNM classification binding at 
that time) in the lymph nodes, and the effect of the adjuvant 
treatment was more significant with the ulceration of primary 
focus. In the group treated with ipilimumab, adverse effects 
occurred in 54% patients with 3–4 toxicity grade in comparison 
with 25% of patients receiving the placebo. On account of the 
complications connected with the administration of ipilimu-
mab, 5 patients (1%) died. Adverse effects led to permanent 
discontinuation of the therapy in 52% patients who had started 
treatment with ipilimumab [20]. 
The median follow-up period in this study was 5.3 years. 
The results pointed to a significant improvement after adjuvant 
therapy with high doses of ipilimumab, both with regards to 
the relapse free survival period as well as the distant metastasis 
free survival and OS. The rate of the 5-year OS in the group 
receiving  ipilimumab was 65.4% in comparison with 54.4% 
in the group with the placebo, the hazard ratio (HR) for death 
was z 0.72; 95.1% and the confidence interval (CI) 0.58–0.88; 
p = 0.001) [21]. 
The preliminary results of another study (E1609) showed 
a similar efficacy of a lower dose of ipilimumab (3 mg/kg 
of body mass) with lower toxicity. The EORTC 18071 study 
resulted in the registration of ipilimumab in the United States 
in the adjuvant treatment of patients with melanomas after 
a lymphadenectomy on account of the metastases in regional 
lymph nodes. However, the practical application of this therapy 
is limited because of its high toxicity and the fact that the trials 
with the anti-PD-1 antibodies (nivolumab and pembrolizumab) 
and kinase inhibitors gave more beneficial results (table II).
The study CheckMate 238 with a random selection of 
patients in clinical IIIB, IIIC and IV stages after resection of 
metastases, showed that after one year of treatment with 
po nivolumab, recurrence-free survival improved by 10% in 
comparison to treatment with ipilimumab; nivolumab showed 
a lower toxicity than ipilimumab (18-month RFS: 65% vs. 53%) 
[22]. This was the only study where patients after the resection 
of distant metastases were included. Moreover, there was an 
improvement in the distant metastases free survival (DMFS): 
HR 0.73). Adverse events, in the 3 or 4 grade,  connected with 
the treatment were observed in 14.4% of patients receiving 
nivolumab in comparison with 45.9% in the group treated with 
ipilimumab [23]. The update of the data from 2018 with the 
longer follow-up period confirmed the beneficial effects of 
nivolumab in the year-long adjuvant treatment irrespective of 
the PD-L1 expression status and BRAF mutation in reference to 
RFS (HR 0.66) and DMFS (HR 0.76) [17]. Nivolumab is currently 
registered for adjuvant treatment in the United States and the 
European Union.
The results of the Keynote-054/EORTC 1325 study with 
the participation of 1019 patients point to a decrease in the 
risk of recurrence (HR for RFS 0.57) and DMFS after one year of 
adjuvant treatment with pembrolizumab in comparison with 
the placebo in the group of patients in stage III, characterised 
Table II. The summary of the most recent clinical studies concerning adjuvant treatment after the resection of melanoma with high recurrence risk 
EORTC 18071
ipilimumab vs. 
placebo
BRIM-8
vemurafenib vs.  
placebo
COMBI-AD
dabrafenib + 
trametinib vs. 
placebo
CheckMate 238
IPI vs. NIVO
EORTC 1325/ 
/Keynote 054
pembrolizumab vs. 
placebo
Author Eggermont 2015 [21] 
Eggermont 2016 [22]
Maio 2018 [29] Long 2017 [26]
Hauschild 2018 [27]
Weber 2017 [22, 23] Eggermont 2018 [24]
Population IIIA (>1 mm), IIIB, IIIC IIC, IIIA, IIIB, IIIC IIIA (>1 mm), IIIB, IIIC IIIB, IIIC, IV IIIA (>1 mm), IIIB, IIIC
BRAF mutation ? 100% 100% 41%/43%
RFS 41% vs. 30% (5 years) 82% vs. 63% (12 months); 
62% vs. 53% (24 months); 
79% vs. 58% (12 months); 
46% vs. 47% (24 months) IIIC; 
84% vs. 66% (12 months); 
72% vs. 56% (24 months) 
IIC–IIIB 
67% vs. 44% (2 years) 
HR = 0,47;
58% vs. 39% (3 years)
66% vs. 53% 
(18 months); 
62.6% vs. 50.2%  
(24 months) 
HR 0.66 
HR 0.65
HR 0.57; difference 
after 18 months 18.2%: 
71.4% vs. 53.2%
OS 65% vs. 54% (5 years)  
HR = 0.72
BD 91% vs. 83% (2 years);
86% vs. 77% (3 years) 
HR = 0.57
BD
OS – overall survival , RFS – recurrence free survival, BD – no data
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with a higher risk (i.e. stage IIIA with the micro-metastasis size 
>1 mm, IIIB and IIIC) [24]. A re-classification with reference 
to a new classification of stage III according to AJCC (eighth 
edition) confirms the benefits with respect to RFS (test for 
interaction: p = 0.68) after one year of treatment with pem-
brolizumab in comparison with the placebo (excluding IIIA 
stage), respectively: 
• IIIB stage (79.0% vs. 65.5%; HR 0.59 [99% CI 0.35–0.99]), 
• IIIC stage (73.6% vs. 53.9%; HR 0.48 [99% CI 0.33–0.70]),
• IIID stage (50.0% vs. 33.3%; HR 0.69 [0.24–2.00]) [25]. 
Currently there is an ongoing study comparing the use of 
nivolumab and the combination of nivolumab with ipilimu-
mab in adjuvant treatment (CheckMate 915). 
Molecularly targeted therapy 
Adjuvant therapy with the use of dabrafenib with trametinib 
in the group of high risk stage III patients with BRAF mutation, 
showed an improvement of RFS (HR 0.47), DMFS (HR 0.51; 91% 
vs. 70% after one year, 77% vs. 60% after 2 year and 71% vs. 
57% after 3 years) and OS (HR 0.57) in comparison with the 
placebo. In this study (COMBI-AD), dabrafenib in combination 
with trametinib were used for a year in comparison with pla-
cebo (IIIA stage with the metastasis size >1 mm, IIIB/C) [26]. 
The benefits in treatment with dabrafenib in combination with 
trametinib were observed in all the analysed subgroups. The 
update of the data from the 4-year follow-up periods confirm 
the benefits of treatment with dabrafenib in combination 
with trametinib (RFS: 54%; HR: 0.49; DFS: 67%; HR: 0.53) [27]. 
Moreover, the model evaluating the cure rate of patients tre-
ated with adjuvant therapy in this case makes up as much as 
17% [27]. The safety profile of dabrafenib in combination with 
trametinib was compliant with the profile observed in the 
study comprising patients with melanoma in stage IV, but the 
entire treatment was relatively well tolerated  (although 26% 
patients discontinued treatment) [28].
Formally, a “positive” clinical study BRIM-8 [29] also con-
cerned the application of vemurafenib in monotherapy in 
adjuvant treatment (in comparison with the placebo). This 
treatment was applied in stage IIC–III patients treated for me-
lanoma after resection (this has so far been the only study 
comprising patients with stage II melanoma). The median 
disease-free survival (DFS) was 23.1 months in the group tre-
ated with vemurafenib, in comparison with 15.4 months in the 
group with the placebo (HR 0.8; p = 0.026), yet this effect was 
limited solely to the subgroup with tumour stage IIC–IIIA–IIIB, 
and was not observed in patients with more advanced me-
lanomas (IIIC). At the same time, we can observe from the 
current experiments carried out with patients with metastatic 
melanomas with the BRAF mutation , that monotherapy with 
BRAF inhibitors is not the optimal treatment method in com-
parison with the combined treatment with  BRAF and MEK 
inhibitors for  these patients. 
Conclusions 
The summary of the results of systemic adjuvant treatment 
with the use of immunotherapy after the resection of high-
-risk melanoma is presented in table II. Other methods of 
immunotherapy (e.g. interleukin 2), vaccinations or cytotoxic 
medication do not have any application in post-operative 
adjuvant treatment [1, 4, 5, 30].
To sum up, in accordance with Polish and American re-
commendations [2, 4, 31] adjuvant treatment with anti-PD-1 
immunotherapy with (nivolumab or pembrolizumab) or com-
bined treatment BRAF and MEK inhibitors (dabrafenib in com-
bination with trametinib for the patient population with the 
BRAF mutation) has become a new therapeutic standard for 
patients after resection of melanomas with a high recurrence 
risk (resection stages IIIA–IV). This, in turn, leads to the fact that 
the cases of all patients with melanomas in stages from IIIA to 
IV should be discussed at multi-specialist team meetings so as 
to guarantee patients optimal, modern, and as effective as po-
ssible treatment options. Additionally, it must be remembered 
that high risk melanomas should be included into prospective 
clinical trials concerning new methods of adjuvant treatment.
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